SV2A-Binding Radioligands for Synaptic Density PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for neurodegenerative and neurological disorders lack effective, non-invasive tools to measure synaptic density accurately, which is crucial for early detection and monitoring of diseases like Alzheimer's, Parkinson's, and multiple sclerosis, as well as for assessing treatment efficacy.
Innovation Solution
Development of compounds that bind to synaptic vesicle glycoprotein 2A (SV2A), allowing for positron emission tomography (PET) imaging to measure synaptic density directly, enabling early diagnosis, disease progression monitoring, and treatment efficacy assessment in various neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If FDG PET is used to measure synaptic function indirectly through glucose metabolism, then neuronal activity can be detected, but the measurement is prone to confounders such as blood glucose level and neuron activation
Solution Approach 1:
The patent introduces SV2A-binding radioligands as an intermediary substance that specifically binds to synaptic vesicle glycoprotein 2A. This intermediary provides a direct measure of synaptic density without the confounding factors affecting glucose metabolism measurements, thereby resolving the contradiction between indirect detection capability and measurement reliability.
2Loss of time
If no validated imaging modality is used for early detection, then current diagnostic methods cannot reliably predict AD progression, but developing new imaging tools requires time and resources
Solution Approach 1:
The patent enables preliminary detection of synaptic density changes before clinical symptoms manifest. By using SV2A-binding radioligands, the system can identify preclinical and prodromal stages of Alzheimer's disease, allowing early intervention before severe neurodegeneration occurs, thus addressing the time loss in early diagnosis.
3Measurement precision
If postmortem histology staining is used for definitive AD diagnosis, then accurate diagnosis can be achieved, but the method is invasive and cannot be used for living patients
Solution Approach 1:
The patent replaces the mechanical/invasive postmortem histology staining method with a non-invasive PET imaging approach using SV2A-binding radioligands. This substitution maintains diagnostic accuracy for synaptic density measurement while enabling assessment in living patients, thus resolving the contradiction between diagnosis accuracy and non-invasiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of SV2A-binding compounds in PET imaging provides a non-invasive, objective measure of synaptic density, facilitating early diagnosis and effective treatment monitoring for neurodegenerative diseases, improving clinical outcomes by enabling timely interventions.
Implementation Method 1
positron emission tomography (PET) imaging
Implementation Method 2
compounds that bind to synaptic vesicle glycoprotein 2A (SV2A)
Data Source
AI summary
In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the brain, measuring synaptic density or diagnosing neurological diseases such as Alzheimer's disease, psychiatric disorders such as depression, and metabolic disorders such as diabetes comprising detecting the compounds of the invention by positron emission tomography (PET).